NEW YORK (GenomeWeb News) — Merck today said that its acquisition of RNAi shop Sirna Therapeutics may close as early as this month.
 
Merck announced its plans to acquire Sirna for $1.1 billion in cash on Oct. 30. At the time, the company said it expected the deal to close by the first quarter of 2007.
Today Merck said it expects the deal to close “in late December 2006 or early in the first quarter of 2007.”
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.